Clinical Trials Logo

Clinical Trial Summary

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).


Clinical Trial Description

The XEN1101 Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled, multicenter study with an optional open-label extension (OLE) to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. Approximately 300 patients will be randomized in a blinded manner to one of three active treatment groups or placebo in a 2:1:1:2 fashion (XEN1101 25 mg : 20 mg : 10 mg : Placebo). After screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 6-week post treatment follow-up period. In order to be included in the study, patients must already be treated with a stable dose of 1 to 3 allowable current anti-epileptic drugs for at least one month prior to screening, during baseline, and throughout the double-blind portion (DBP) of the study. During the treatment period, patients will be given XEN1101 or placebo once daily in the evening. A five year OLE will be available to eligible patients who complete the DBP. All patients will receive a 20 mg daily dose of XEN1101 during this extension period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03796962
Study type Interventional
Source Xenon Pharmaceuticals Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 30, 2019
Completion date October 2026

See also
  Status Clinical Trial Phase
Recruiting NCT02245061 - Cortical Excitability Assessment Using Paired Pulses N/A
Terminated NCT05081518 - A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy Phase 1
Withdrawn NCT05481905 - ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures Phase 2
Completed NCT02208492 - The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study Phase 4
Recruiting NCT04839601 - RNS System RESPONSE Study N/A
Completed NCT02898935 - Improvement of the Accuracy of Spatial Representation of Invasive Exploratory Electrodes in Focal Epilepsy
Enrolling by invitation NCT05748236 - The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy Phase 4
Terminated NCT01724918 - Lacosamide IV and EEG/EKG (LIVE) Study Phase 2
Completed NCT00855738 - A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice Phase 4
Not yet recruiting NCT06210022 - Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
Completed NCT01311440 - Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy N/A
Terminated NCT03955432 - Long-term Cardiac Monitoring in Epilepsy N/A
Recruiting NCT06132893 - A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Phase 2/Phase 3
Recruiting NCT05100771 - Optimized Volumetry in Radiology: Interest in Pediatric Brain MRI in the Exploration of Focal Epilepsy
Recruiting NCT04879433 - Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy
Active, not recruiting NCT03916848 - Novel Network Analysis of Intracranial Stereoelectroencephalography N/A
Recruiting NCT05198882 - Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy Phase 1
Recruiting NCT05981755 - Breathing Rescue for SUDEP Prevention N/A
Recruiting NCT03457961 - Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
Completed NCT03082222 - ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions